Project Grant SB1GM157775

Award Date 7/15/25
Completion Date 3/31/28
Dollars Obligated $1M
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Mountain View, CA 94043, USA
Similar Awards
The National Institute of General Medical Sciences (NIGMS) awarded a $356,497 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Kinetic River Corp. in Mountain View, CA. This grant, awarded on August 15, 2024, is funding the development of an ultrasensitive flow cytometry system for multiparametric analysis of therapeutic anti-aging extracellular vesicles (EVs). Extracellular vesicles show promise as biomarkers and therapeutics for a range of indications,...
The National Institute of General Medical Sciences (NIGMS) awarded a $243,119 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to the University of Puerto Rico Medical Sciences Campus (UPR-MSC). This award will enable the purchase of a state-of-the-art BD FACSymphony A1 flow cytometer with 4 lasers to support health-related research projects and educational needs at UPR-MSC. The flow cytometer will allow for the advanced analysis of immune cells and other...
This Project Grant award, funded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), provides $478,832 to the MaineHealth Institute for Research (MHIR) to acquire a BD FACSymphony A5 SE flow cytometry system. This high-dimensional instrument will significantly enhance MHIR's research capabilities by enabling advanced analysis of cells and extracellular vesicles, supporting ongoing NIH-funded studies and...
This $306,872 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of a commercial prototype for Fluid Discovery, Inc.'s "Universal Platform for Ultrahigh-Throughput Biocatalyst Evolution with Micro-Mass Spectrometry." This transformative screening platform combines scalable hardware, label-free mass spectrometry, and advanced computational techniques to...
The National Institute of General Medical Sciences (NIGMS) awarded a $349,816 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Narwhal Bio, Inc. in San Diego, CA. The grant supports the development of a prototype instrument, software, and consumable for non-invasive live-cell identification, tagging, and downstream characterization. This novel platform aims to enable researchers to study clinically relevant cell-cell interactions that drive diseases like...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) is funding the development of a Spotting-Free Nano-Oscillator Array (SFNOA) technology by Biosensing Instrument Inc. The SFNOA system aims to enable high-throughput, label-free quantification of ligand binding kinetics to transmembrane proteins in their native states. The $349,566 award, effective from April 2, 2025 to March 31, 2026,...
This Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), is funding the development of novel signal amplification technologies by Molecular Instruments, Inc. to enable automated, ultrasensitive, and multiplex imaging of RNA and protein expression in biological samples. The $1,099,625 award supports the engineering of two key capabilities: 1) a chromogenic signal amplification...
The National Institute of General Medical Sciences (NIGMS) awarded a $366,250 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Central Michigan University. The grant, which runs from January 1, 2025 to December 31, 2029, aims to develop bioluminescent kinase sensors to monitor and manipulate cell signaling processes related to cell growth, division, and the cell cycle. The proposed research seeks to create novel tools for studying cell biology and...
The National Institute of General Medical Sciences (NIGMS) awarded a $304,862 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Edvotek Inc., a for-profit company located in Washington, DC. The grant supports the development of the StemFluidics Platform, an innovative microfluidics system designed to enable safe and reproducible hands-on experiments for students to explore biotechnology concepts in classroom settings. The StemFluidics Platform features an...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) will provide $208,915 to St. Mary's University of San Antonio, Texas to acquire a Beckman Coulter CytoFLEX flow cytometry instrument. The instrument will be housed in a collaborative lab space at the university to support scientific research and educational projects across basic, translational, and biomedically-related disciplines. The...

The National Institute of General Medical Sciences (NIGMS) awarded a $999,998 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Kinetic River Corp. of Mountain View, CA. The grant supports the development and refinement of Kinetic River's ARNO flow cytometer, which eliminates the need for spectral compensation in advanced flow cytometry analysis. Specifically, the funding will enable Kinetic River to:

  1. Reduce the cost of the ARNO's data acquisition module by 50% to enhance affordability and accessibility for smaller research labs and flow core facilities.

  2. Implement an improved time-resolved fluorescence discrimination algorithm for the ARNO, integrating empirical data from a broader range of common dyes and fluorescent proteins. This will expand the ARNO's utility by enabling compensation-free analysis using a wider selection of fluorescent markers.

The project period runs from July 2025 through March 2028, with the goal of significantly advancing the ARNO flow cytometer's capabilities and driving increased adoption within the biomedical research community.

Generated 8/5/25, 5:50 AM